Amgen Contingent Consideration Liability (Non-Current) increased by 5.6% to $95.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 15.2%, from $112.00M to $95.00M. Over 4 years (FY 2020 to FY 2024), Contingent Consideration Liability (Non-Current) shows an upward trend with a 33.9% CAGR.
An increase often indicates successful integration or high performance of acquired assets triggering earn-outs, while a decrease may signal missed targets or the settlement of obligations.
This represents the long-term portion of obligations to pay additional consideration to sellers in connection with past...
Standard for companies with active M&A strategies and earn-out structures in purchase agreements.
contingent_consideration_liability_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.00M | $35.00M | $342.00M | $330.00M | $310.00M | $302.00M | $270.00M | $273.00M | $248.00M | $98.00M | $96.00M | $96.00M | $107.00M | $112.00M | $106.00M | $104.00M | $90.00M | $95.00M |
| QoQ Change | — | -27.1% | +877.1% | -3.5% | -6.1% | -2.6% | -10.6% | +1.1% | -9.2% | -60.5% | -2.0% | +0.0% | +11.5% | +4.7% | -5.4% | -1.9% | -13.5% | +5.6% |
| YoY Change | — | — | — | — | +545.8% | +762.9% | -21.1% | -17.3% | -20.0% | -67.5% | -64.4% | -64.8% | -56.9% | +14.3% | +10.4% | +8.3% | -15.9% | -15.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.